Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 2c; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.59 --0%
Financial Fact:
Research and development: 3.76M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development: 3.76M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $40.27 million versus the consensus estimate of $43.29 million.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
